Capture assays, such as pregnancy and Covid-19 antigen tests, represent the most popular current application of μPADs. In these assays, capillary-driven flow is harnessed to minimize the number of user operations (most notably washing steps) compared to plate-based assays, making these devices particularly suitable for decentralized testing. Recently, the introduction of CRISPR-based biosensing has expanded our collective ability to perform molecular diagnostics at the point of care . An excellent example is the DNA Endonuclease-Targeted CRISPR Trans Reporter (DETECTR) assay, which combines recombinase polymerase amplification (RPA) with CRISPR/Cas12a signal generation to detect viral genomes with exceptional sensitivity and on short timescales . As the field expands, the need for methods that detect CRISPR reporters using minimal instrumentation is becoming more pressing . With this in mind, and as a proof of concept, we developed a rapid electrochemical capture assay for HPV16, a high-risk carcinogenic subtype of HPV that benefits from early detection . Our approach integrates the DETECTR assay with electrochemical detection of the CRISPR reporters within our low-cost platform. Due to the 'signal-off' nature of reporter detection (i.e. a strong positive sample leads to a low signal), electrochemical readout is highly advantageous, as it simplifies result interpretation by providing an unambiguous digital result for the untrained user.